1
|
Romero-Torrecilla JA, Lamo-Espinosa JM, Ripalda-Cemboráin P, López-Martínez T, Abizanda G, Riera-Álvarez L, de Galarreta-Moriones SR, López-Barberena A, Rodríguez-Flórez N, Elizalde R, Jayawarna V, Valdés-Fernández J, de Anleo MEG, Childs P, de Juan-Pardo E, Salmeron-Sanchez M, Prósper F, Muiños-López E, Granero-Moltó F. An engineered periosteum for efficient delivery of rhBMP-2 and mesenchymal progenitor cells during bone regeneration. NPJ Regen Med 2023; 8:54. [PMID: 37773177 PMCID: PMC10541910 DOI: 10.1038/s41536-023-00330-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 09/14/2023] [Indexed: 10/01/2023] Open
Abstract
During bone regeneration, the periosteum acts as a carrier for key regenerative cues, delivering osteochondroprogenitor cells and crucial growth factors to the injured bone. We developed a biocompatible, 3D polycaprolactone (PCL) melt electro-written membrane to act as a mimetic periosteum. Poly (ethyl acrylate) coating of the PCL membrane allowed functionalization, mediated by fibronectin and low dose recombinant human BMP-2 (rhBMP-2) (10-25 μg/ml), resulting in efficient, sustained osteoinduction in vitro. In vivo, rhBMP-2 functionalized mimetic periosteum demonstrated regenerative potential in the treatment of rat critical-size femoral defects with highly efficient healing and functional recovery (80%-93%). Mimetic periosteum has also proven to be efficient for cell delivery, as observed through the migration of transplanted periosteum-derived mesenchymal cells to the bone defect and their survival. Ultimately, mimetic periosteum demonstrated its ability to deliver key stem cells and morphogens to an injured site, exposing a therapeutic and translational potential in vivo when combined with unprecedentedly low rhBMP-2 doses.
Collapse
Affiliation(s)
- Juan Antonio Romero-Torrecilla
- Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain
- Biomedical Engineering Program, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
| | - José María Lamo-Espinosa
- Department of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Purificación Ripalda-Cemboráin
- Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain
- Biomedical Engineering Program, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
- Department of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Tania López-Martínez
- Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain
- Biomedical Engineering Program, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
| | - Gloria Abizanda
- Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain
- Biomedical Engineering Program, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
| | - Luis Riera-Álvarez
- Department of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Pamplona, Spain
| | | | | | - Naiara Rodríguez-Flórez
- Tecnun-School of Engineering, Universidad de Navarra, San Sebastian, Spain
- IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| | - Reyes Elizalde
- Tecnun-School of Engineering, Universidad de Navarra, San Sebastian, Spain
| | - Vineetha Jayawarna
- Center for the Cellular Microenvironment, James Watt School of Engineering, University of Glasgow, Glasgow, United Kingdom
| | - José Valdés-Fernández
- Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain
- Biomedical Engineering Program, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
| | - Miguel Echanove-González de Anleo
- Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain
- Biomedical Engineering Program, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
| | - Peter Childs
- Department of Biomedical Engineering, University of Strathclyde, Glasgow, United Kingdom
| | - Elena de Juan-Pardo
- T3mPLATE, Harry Perkins Institute of Medical Research, Queen Elizabeth II Medical Centre and the UWA Centre for Medical Research, The University of Western Australia, Perth, Australia
| | - Manuel Salmeron-Sanchez
- Center for the Cellular Microenvironment, James Watt School of Engineering, University of Glasgow, Glasgow, United Kingdom
| | - Felipe Prósper
- Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain
- Biomedical Engineering Program, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Pamplona, Spain
- Department of Hematology, Clínica Universidad de Navarra, Pamplona, Spain
| | - Emma Muiños-López
- Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
- Biomedical Engineering Program, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
- Department of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Pamplona, Spain.
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain.
| | - Froilán Granero-Moltó
- Cell Therapy Area, Clínica Universidad de Navarra, Pamplona, Spain.
- Biomedical Engineering Program, Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.
- Department of Orthopedic Surgery and Traumatology, Clínica Universidad de Navarra, Pamplona, Spain.
- Instituto de Investigaciones Sanitarias de Navarra (IdiSNA), Pamplona, Spain.
| |
Collapse
|